RE: Not sweating it9 Dec 2021 14:42
AZD1656 is a potent and selective activator of glucokinase that was being
developed by AZN for type II diabetes. SGSC recognised that the effects of
AZD1656 on immune function might be useful to treat people with diabetes that
had become infected with COVID-19. This was confirmed during 2021, with
encouraging results in a Phase II clinical trial, known as ARCADIA, in 150 patients
with either type I or type II diabetes, who were hospitalised with mild-to-moderate
COVID-19. There was a strong trend towards reduced mortality in patients
receiving AZD1656. Data from ARCADIA support the continued investigation of
AZD1656 for the treatment of patients with COVID-19, with or without diabetes,
and SGSC is now considering its options to progress AZD1656 through a Phase III
trial.